Literature DB >> 23032738

Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings.

Lynn A Paxton1.   

Abstract

PURPOSE OF REVIEW: To discuss the factors pertinent to the use of pre-exposure prophylaxis (PrEP) by at-risk heterosexuals in countries with generalized HIV epidemics. RECENT
FINDINGS: PrEP will have the greatest prevention effect if targeted to those at highest risk, but identifying and engaging such persons is challenging. Serodiscordant couples account for a high proportion of new infections and are an appropriate target for PrEP, but the proportion of people in such relationships is small and outside partnerships are common. Differences in adherence coupled to pharmacology of the drugs may account for differences in efficacy seen in the trials. Mathematical modeling indicates that the benefits of PrEP in highly endemic settings outweigh the risk of induced viral resistance. Behavioral risk compensation was not observed in the trials, but current open-label studies will better determine if disinhibition will be an important problem.
CONCLUSIONS: PrEP is a potentially useful HIV-prevention strategy for generalized heterosexual epidemics. Optimal implementation will require learning more about ways to improve acceptability and adherence and how best to deliver PrEP within the context of limited resource availability.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23032738     DOI: 10.1097/COH.0b013e328359064a

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  4 in total

1.  Safety and tolerability of tenofovir for preexposure prophylaxis among men who have sex with men.

Authors:  Sten H Vermund
Journal:  J Acquir Immune Defic Syndr       Date:  2013-09-01       Impact factor: 3.731

Review 2.  A new paradigm for optimizing HIV intervention synergy: the role of interdependence in integrating HIV prevention interventions.

Authors:  Gina M Wingood; Anna Rubtsova; Ralph J DiClemente; David Metzger; Michael Blank
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

3.  PrEP Implementation Science: State-of-the-Art and Research Agenda.

Authors:  Carlos F Cáceres; Kenneth H Mayer; Rachel Baggaley; Kevin R O'Reilly
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

4.  The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.

Authors:  Carlos F Cáceres; Florence Koechlin; Pedro Goicochea; Papa-Salif Sow; Kevin R O'Reilly; Kenneth H Mayer; Peter Godfrey-Faussett
Journal:  J Int AIDS Soc       Date:  2015-07-20       Impact factor: 5.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.